Related Experiment Video
Updated: Feb 13, 2026
12:03
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
18.5K
Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Promising Medication for Chronic
Ioannis E Vasileiadis1, Christos A Goudis2, Pinelopi T Giannakopoulou1
1a Department of Cardiology , General Hospital of Thessaloniki G. Papanikolaou , Thessaloniki , Greece.
COPD
|March 10, 2018
Summary
Chronic obstructive pulmonary disease (COPD) involves lung and systemic inflammation. This review explores how blocking the renin-angiotensin system (RAS) may benefit COPD patients with cardiovascular issues.
Area of Science:
- Pulmonary Medicine
- Cardiovascular Medicine
- Pharmacology
Background:
- Chronic obstructive pulmonary disease (COPD) is characterized by local pulmonary and systemic inflammation.
- Systemic inflammation in COPD contributes to extrapulmonary and cardiovascular co-morbidities.
- Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are common cardiovascular treatments.
Purpose of the Study:
- To elucidate the connection between the renin-angiotensin system (RAS) and COPD pathophysiology.
- To review current evidence on the potential therapeutic role of RAS blockers in COPD management.
Main Methods:
- Literature review of studies investigating RAS involvement in COPD.
- Analysis of data on ACE inhibitors and ARBs in COPD patients.
- Synthesis of information on RAS blockers and their impact on COPD-related co-morbidities.
Main Results:
- The renin-angiotensin system plays a role in COPD pathophysiology.
- Evidence suggests potential benefits of ACE inhibitors and ARBs in COPD patients.
- RAS blockers may help manage cardiovascular co-morbidities associated with COPD.
Conclusions:
- The renin-angiotensin system is implicated in the complex mechanisms of COPD.
- RAS blockers represent a potential therapeutic avenue for COPD patients, particularly those with cardiovascular disease.
- Further research is warranted to fully understand the efficacy and safety of RAS blockers in COPD.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.6K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.6K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.8K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.8K
01:24Chronic Obstructive Pulmonary Disease
2.6K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.6K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
4.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
4.7K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
3.9K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.9K
01:29Chronic Obstructive Pulmonary Disease-V: Management
3.3K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.3K